Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Amit Sanyal, MD: A Clinician’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Jul

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Amit Sanyal, MD: A Clinician’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

People With Acromegaly Face Elevated Cancer Risk, Study Finds

Resectable NSCLC Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy

Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers

New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies

MRD-Guided Therapy With Ibrutinib-Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia